Novartis Ag (NVS) FCF Margin Growth (3y) (2012 - 2026)
Novartis Ag (NVS) FCF Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1,461.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2,596.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 874.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 536.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1,444.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -2,024.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1,067.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 6,281.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -1,843.00 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 1,072.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 536.00 |
| Mar 31, 2026 | 5,428.00 |
| Dec 31, 2025 | 15,863.00 |
| Sep 30, 2025 | -602.00 |
| Jun 30, 2025 | 1,367.00 |
| Mar 31, 2025 | 10,320.00 |
| Dec 31, 2024 | 2,981.00 |
| Jun 30, 2024 | 645.00 |
| Mar 31, 2024 | -26,628.00 |
| Dec 31, 2023 | -38.00 |
| Sep 30, 2023 | 11,791.00 |
| Jun 30, 2023 | -377.00 |
| Mar 31, 2023 | -4,731.00 |
| Dec 31, 2022 | -27,790.00 |
| Sep 30, 2022 | 22,587.00 |
| Jun 30, 2022 | 257.00 |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | -19,292.00 |
| Sep 30, 2021 | -121,256.00 |
| Jun 30, 2021 | -237.00 |